Historical record - last NADAC effective date: 5/18/2022
Product Information
IBUPROFEN 400 MG TABLET is a generic product labeled by Amneal Pharmaceuticals NY LLC, priced at $0.0481 per EA under NDC 69238110105. Its NADAC has been published 375 times since Apr 1, 2015.
FDA first approved this application on Feb 5, 2009. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
400 mg/1
Manufacturer
Amneal Pharmaceuticals NY LLCNDC
69238110105
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
5/18/2022
Active Ingredients
IBUPROFENApproval Type
Generic (ANDA)
FDA Application
ANDA078329FDA Approved
2/5/2009
TE Code
AB
On Market Since
4/1/2014
Pharmacological Classes
Price Statistics
The NADAC for IBUPROFEN 400 MG TABLET has been published 375 times since Apr 1, 2015, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0481 per EA |
|---|---|
| All-time high | $0.0577 (Sep 15, 2021) |
| All-time low | $0.0336 (Sep 19, 2018) |
| Median price | $0.0469 |
| Average price | $0.0468 |
| Largest weekly change | +22.9% (Jan 23, 2019) |
| Weeks tracked | 375 |
| Tracking since | Apr 1, 2015 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
-11.4%
All
+0.0%
Last surveyed Jun 1, 2022 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 13 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 19% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Amneal Pharmaceuticals NY LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Ibuprofen market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nonsteroidal Anti-inflammatory Drug class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of IBUPROFEN 400 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for IBUPROFEN 400 MG TABLET, manufactured by Amneal Pharmaceuticals NY LLC, is $0.0481 per EA (NDC 69238110105), effective Jun 1, 2022.
How has the price of IBUPROFEN 400 MG TABLET changed over time?
Over the history we have for it, the NADAC for IBUPROFEN 400 MG TABLET has held within roughly two percent of its current level. It has been tracked across 375 weekly CMS publications since Apr 1, 2015.
What are the highest and lowest recorded NADAC prices for IBUPROFEN 400 MG TABLET?
Since Apr 1, 2015, the NADAC for IBUPROFEN 400 MG TABLET has ranged from a low of $0.0336 (Sep 19, 2018) to a high of $0.0577 (Sep 15, 2021), with a median of $0.0469 per EA.
Are there cheaper alternatives to IBUPROFEN 400 MG TABLET?
Yes. 13 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, IBUPROFEN 400 MG TABLET, is $0.0390 per EA — about 19% below IBUPROFEN 400 MG TABLET.
Who manufactures IBUPROFEN 400 MG TABLET?
IBUPROFEN 400 MG TABLET (NDC 69238110105) is labeled by Amneal Pharmaceuticals NY LLC, and CMS classifies it as a generic product.